Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185065 · ClinicalTrials.gov registry record · Phase 3
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT03185065: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT03185065 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 141 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185065, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.
Interventions
- DRUG Placebos
- DRUG Methylphenidate
- DRUG Modafinil
- DRUG Amantadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2019-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185065
The ClinicalTrials.gov registry entry for NCT03185065 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebos is the first listed.
NCT03185065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03185065 about?
NCT03185065 is a clinical study titled "Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis". Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonal...
What is the current status of trial NCT03185065?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2017-10-04. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03185065?
The interventions under investigation include: Placebos (DRUG), Methylphenidate (DRUG), Modafinil (DRUG), Amantadine (DRUG).
Who is sponsoring clinical trial NCT03185065?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.